RIZLAB HEALTH INC - RESEARCH AND DEVELOPMENT- AOI #16+ SEEKING TO MANUFACTURE AND OBTAIN REGULATORY APPROVAL FOR THE CYTOTRACKER BV, A POINT-OF-CARE INSTANT WHITE BLOOD CELL ANALYSIS PLATFORM FOR DISCRIMINATING BETWEEN ACUTE VIRAL AND BACTERIAL INFECTIONS.

On Feb 9, 2026, Department of Health and Human Services obligated $2,483,472 to RIZLAB HEALTH INC for research and development- aoi #16+ seeking to manufacture and obtain regulatory approval for the cytotracker bv, a point-of-care instant white blood cell analysis platform for discriminating between a…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in PRINCETON, NJ. The contract is scheduled through Apr 10, 2027 — approximately 10 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.